Efficacy and Safety of Tildrakizumab in the Treatment of Scalp Psoriasis

NCT ID: NCT03897088

Last Updated: 2023-05-31

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 231 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-03-29
• Study Completion Date: 2022-02-17

Brief Summary

This is a multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of tildrakizumab in the treatment of moderate to severe psoriasis of the scalp.

Conditions

Scalp Psoriasis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Tildrakizumab

Group Type: EXPERIMENTAL

PART 1: Double-blind Placebo-controlled

Intervention Type: DRUG

all eligible subjects will receive either tildrakizumab or placebo

PART 2: Double-blind Active Treatment Extension

Intervention Type: DRUG

subjects initially on placebo will be switched over to receive tildrakizumab while subjects initially on tildrakizumab will continue to receive tildrakizumab as per defined schedule

Placebo

Group Type: PLACEBO_COMPARATOR

PART 1: Double-blind Placebo-controlled

Intervention Type: DRUG

all eligible subjects will receive either tildrakizumab or placebo

PART 3: Observational Safety Follow-up

The subjects will not receive study treatment during the follow-up period

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

PART 1: Double-blind Placebo-controlled

all eligible subjects will receive either tildrakizumab or placebo

Intervention Type: DRUG

PART 2: Double-blind Active Treatment Extension

subjects initially on placebo will be switched over to receive tildrakizumab while subjects initially on tildrakizumab will continue to receive tildrakizumab as per defined schedule

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Subjects should be 18 years or older at the time of signing the informed consent during the Screening visit.

2. Subjects with a clinical diagnosis of chronic plaque psoriasis of at least 6 months (as determined by-subject interview and confirmation of diagnosis through physical examination by Investigator).

3. Subjects must have moderate to severe plaque psoriasis of the scalp at Screening and at Baseline, defined by:

• Scalp Investigator Global Assessment (IGA) of ≥3
• Psoriasis Scalp Severity Index (PSSI) score of ≥12
• ≥30% or scalp surface area affected.

4. Subject must have moderate to severe plaque psoriasis at Screening and Baseline defined by

• Physician Global Assessment for Skin (PGA-S) of at least moderate severity (score of ≥3 on a 5-pointer scale)
• PASI score of ≥12
• Body Surface Area (BSA) involvement of >10%

5. Subjects must be considered candidates for systemic therapy, meaning scalp psoriasis inadequately controlled by topical treatments (corticosteroids), and/or phototherapy, and/or previous systemic therapy.

6. Subjects has a negative evaluation for tuberculosis (TB) within 4 weeks before initiating study treatment, defined as a negative QuantiFERON® test. Subjects with a positive or 2 successive indeterminate. QuantiFERON® tests are allowed if they have all of the following:

• No history of active TB or symptoms of TB.
• A posterior-anterior chest radiogram (with associated report available at study center) performed within 3 months of Screening with no evidence of active TB (or of any other pulmonary infectious diseases).
• If prior latent TB infection (LTBI), must have history of adequate prophylaxis (per local standard of care).
• If presence of LTBI is established, then treatment according to local country guidelines must have been followed for 4 weeks prior to inclusion in the study.

A maximum of 2 QuantiFERON® tests are allowed. A re-test is only permitted if the first is indeterminate; the result of the second test will then be used.

7. Subjects are unlikely to conceive, as indicated by at least one "Yes" answer to the following questions:

• Subject is a male.
• Subject is a female and agrees to abstain from heterosexual activity OR use a highly effective method of contraception as per Appendix 7.
• Male subjects with female partners of childbearing potential who are not using birth control as described above must use a barrier method of contraception (eg, condom) if not surgically sterile (ie, vasectomy).
• Subject is a surgically sterilized female or is documented to be postmenopausal. For contraceptive guidance see Appendix 7.

8. For women of childbearing potential, a negative serum pregnancy test at Screening and a negative urine pregnancy test within 24 hours prior to Day 1 and on subsequent visits at which study treatment doses are scheduled.

9. Subjects must have results of a physical examination within normal limits or clinically acceptable limits to the Investigator prior to Day 1. The Investigator is encouraged to consult with the Medical Monitor (or appropriate designee) if there are questions regarding the significance of any out-of-range values.

10. Subjects must be capable of giving signed informed consent as described in Appendix 2, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.

Exclusion Criteria

1. Subjects who have laboratory abnormalities at Screening including any of the following:

• Alanine aminotransferase or aspartate aminotransferase ≥2.5 × the upper limit of normal
• Creatinine ≥2 × the upper limit of normal
• Serum direct bilirubin ≥1.5 mg/dL
• White blood cell count <3.0×103/μL
• Any other laboratory abnormality, which, in the opinion of the Investigator, will prevent the subject from completing the study or will interfere with the interpretation of the study results.

2. Subjects who have predominantly non-plaque forms of psoriasis specifically erythrodermic psoriasis, predominantly pustular psoriasis, medication-induced or medication-exacerbated psoriasis, or new-onset guttate psoriasis.

3. Women of childbearing potential who are pregnant, intend to become pregnant (within 6 months of completing the study), or are lactating.

4. Subjects with any infection or history of recurrent infection requiring treatment with systemic antibiotics within 2 weeks prior to Screening, or severe infection (eg, pneumonia, cellulitis, bone or joint infections) requiring hospitalization or treatment with intravenous (IV) antibiotics within 6 weeks prior to Screening.

5. Subjects with any previous use of tildrakizumab or other IL-23/Th-17 pathway inhibitors, including p40, p19 and IL-17 antagonists for psoriasis.

• Prior use of TNF-alpha inhibitors with a wash-out period of 12 weeks would be allowed. However, the number of subjects with prior use of TNF-alpha inhibitors would be capped at 40% and the analysis will be stratified based on prior use of these biologics.

6. Subjects with a positive human immunodeficiency virus test result, hepatitis B surface antigen, or hepatitis C virus test result.

7. Subjects with a prior malignancy or concurrent malignancy (excluding successfully treated basal cell carcinoma, squamous cell carcinoma of the skin in situ, squamous cell carcinoma of skin with no evidence of recurrence within 5 years or carcinoma in situ of the cervix that has been adequately treated).

8. Subjects who have received live viral or bacterial vaccination within 4-weeks prior to Baseline or who intend to receive live viral or bacterial vaccination during the study.

9. Subjects who are currently participating in another interventional clinical study or has participated in an interventional clinical study within 5-half-lives (of the drug) to wash-out prior to randomization (Subjects participating in observational studies or non-interventional registry studies may be included in the study).

10. Subjects or a family member is among the personnel of the study center or Sponsor/designee staff directly involved with this study.

11. Subjects who have any concomitant medical condition which in the opinion of the Investigator could affect the study outcome or present an unacceptable risk.

12. Subjects who were hospitalized due to an acute cardiovascular event (such as myocardial infarction, cerebrovascular accident, cardiovascular illness [eg, angina pectoris], or cardiovascular surgery [such as coronary artery bypass grafting]) within 6 months before Screening.

13. Subjects who, in the opinion of the Investigator, will not be a reliable participant in the study and those who can confound the results of the study.

14. Subjects who have a history of alcohol or drug abuse in the previous year.

15. Subjects who have high risk of suicidality at the Screening assessment based on Investigator's judgment or, if appropriate, as indicated by a response of "yes" within the last 12 months to Questions 4 or 5 in the suicidal ideation section, or any positive response in the behavioral section of the Columbia-Suicide Severity Rating Scale

16. Subjects with any other clinically significant laboratory abnormality, which, in the opinion of the Investigator, will prevent the subject from completing the study or will interfere with the interpretation of the study results.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sun Pharmaceutical Industries Limited

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

SPARC Site 18

Encinitas, California, United States

SPARC Site 7

Fountain Valley, California, United States

SPARC Site 3

Fremont, California, United States

SPARC Site 12

Huntington Beach, California, United States

SPARC Site 9

Los Angeles, California, United States

SPARC Site 2

Los Angeles, California, United States

SPARC Site 14

Santa Monica, California, United States

SPARC Site 21

Coral Gables, Florida, United States

SPARC Site 19

Margate, Florida, United States

SPARC Site 5

Sweetwater, Florida, United States

SPARC Site 13

East Windsor, New Jersey, United States

SPARC Site 4

Forest Hills, New York, United States

SPARC Site 16

New York, New York, United States

SPARC Site 01

Beachwood, Ohio, United States

SPARC Site 20

Portland, Oregon, United States

SPARC Site 8

Johnston, Rhode Island, United States

SPARC Site 17

Cypress, Texas, United States

SPARC Site 11

Houston, Texas, United States

SPARC Site 6

Webster, Texas, United States

SPARC Site 23

Kogarah, New South Wales, Australia

SPARC Site 27

Kogarah, New South Wales, Australia

SPARC Site 26

Woolloongabba, Queensland, Australia

SPARC Site 25

Carlton, Victoria, Australia

SPARC Site 24

East Melbourne, Victoria, Australia

SPARC Site 22

Fremantle, Western Australia, Australia

Countries

United States; Australia

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

TILD-18-20

Identifier Type: -

Identifier Source: org_study_id